Journal article icon

Journal article

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

Abstract:

Background

The EQUATOR trial investigated the efficacy and safety of filgotinib, a selective Janus kinase 1 (JAK1) inhibitor, for the treatment of psoriatic arthritis (PsA).

Methods

This completed, randomised, double-blind, placebo-controlled phase 2 trial enrolled adults from 25 centres in seven countries (ClinicalTrials.gov identifier: NCT03101670). Patients had active moderate-to-severe PsA fulfilling Classification for PsA (CASPAR) criteria and insufficient re...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted Manuscript

Actions


Access Document


Files:
Publisher copy:
10.1016/S0140-6736(18)32483-8

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS
Subgroup:
Botnar Research Centre
ORCID:
0000-0002-4756-663X
Helliwell, PS More by this author
Stanislavchuk, M More by this author
Rychlewska-Hanczewska, A More by this author
Expand authors...
Galapagos NV More from this funder
Gilead Sciences, Inc More from this funder
Publisher:
Elsevier Publisher's website
Journal:
Lancet Journal website
Volume:
392
Issue:
10162
Pages:
P2367-2377
Publication date:
2018-10-22
Acceptance date:
2018-10-03
DOI:
EISSN:
1474-547X
ISSN:
0140-6736
Pubs id:
pubs:923353
URN:
uri:4edadb75-917f-4a51-a319-707d56c296b3
UUID:
uuid:4edadb75-917f-4a51-a319-707d56c296b3
Local pid:
pubs:923353

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP